Related Funds
Funds with similar focus
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Synnovation Therapeutics | $102M | 14 Dec 2023 | Wilmington, Delaware, United States | ||
ADARx Pharmaceuticals | $46M | 20 Jan 2023 | San Diego, California, United States | ||
ArriVent Biopharma | $155M | 29 Dec 2022 | Pennsylvania Furnace, Pennsylvania, United States | ||
Fuse Biotherapeutics | $9M | 15 Nov 2021 | Los Angeles, California, United States | ||
ADARx Pharmaceuticals | $75M | 08 Sep 2021 | San Diego, California, United States | ||
Antiva Biosciences | $15M | 10 Jul 2018 | California, United States | ||
Arvinas | $55M | 04 Apr 2018 | New Haven, Connecticut, United States | ||
TCR2 | $125M | 21 Mar 2018 | Cambridge, Massachusetts, United States | ||
$282M | 28 Feb 2018 | Maryland, United States |
– ADARx Pharmaceuticals, Inc. completed a $75m Series B financing.
– The round was co-led by SR One Capital Management and OrbiMed Advisors.
– Sirona Capital joined this financing as well as existing investor Lilly Asia Ventures.
– The proceeds from the Series B financing will be used to advance ADARx’s proprietary RNA platform technologies for base editing, inhibition, degradation, and delivery.
– The proceeds will also be used to transition ADARx’s growing pipeline of research phase products into the clinic including initiation of a Phase 1 clinical trial for ADARx’s lead program.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Synnovation Therapeutics | $102M | 14 Dec 2023 | Wilmington, Delaware, United States | ||
ADARx Pharmaceuticals | $46M | 20 Jan 2023 | San Diego, California, United States | ||
ArriVent Biopharma | $155M | 29 Dec 2022 | Pennsylvania Furnace, Pennsylvania, United States | ||
Fuse Biotherapeutics | $9M | 15 Nov 2021 | Los Angeles, California, United States | ||
ADARx Pharmaceuticals | $75M | 08 Sep 2021 | San Diego, California, United States | ||
Antiva Biosciences | $15M | 10 Jul 2018 | California, United States | ||
Arvinas | $55M | 04 Apr 2018 | New Haven, Connecticut, United States | ||
TCR2 | $125M | 21 Mar 2018 | Cambridge, Massachusetts, United States | ||
$282M | 28 Feb 2018 | Maryland, United States |